Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
27
Frequently Asked Questions
What is Market Cap of Zynerba Pharmaceuticals Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Zynerba Pharmaceuticals Inc market cap is $70.12M.
What is the 52-week high for Zynerba Pharmaceuticals Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Zynerba Pharmaceuticals Inc 52 week high is $1.40 as of September 22, 2025.
What is the 52-week low for Zynerba Pharmaceuticals Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Zynerba Pharmaceuticals Inc 52 week low is $0.25 as of September 22, 2025.
What is Zynerba Pharmaceuticals Inc stock price today?
Zynerba Pharmaceuticals Inc stock price today is $1.30.
What was Zynerba Pharmaceuticals Inc stock price yesterday?
Zynerba Pharmaceuticals Inc stock price yesterday was $1.27.
What is the PE ratio of Zynerba Pharmaceuticals Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Zynerba Pharmaceuticals Inc’s P/E ratio is -1.63.
What is the Price-to-Book ratio of Zynerba Pharmaceuticals Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Zynerba Pharmaceuticals Inc P/B ratio is 2.4163.
What is Zynerba Pharmaceuticals Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Zynerba Pharmaceuticals Inc's EBITDA is 0.50.
What is the 50-day moving average of Zynerba Pharmaceuticals Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Zynerba Pharmaceuticals Inc 50-day moving average is $1.19.
How many employess does Zynerba Pharmaceuticals Inc has?
